CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-27..
Quick ratio
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.13B USD | Liabilities, Current |
| Cash and equivalents | 192.03M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 711.75M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 346.26M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-27 | (m) | $1.13B | $192.03M | (m) | $711.75M | $346.26M | (m) |
| 2026-03-28 | (m) | $1.09B | $191.83M | (m) | $700.25M | $359.72M | (m) |
| 2025-12-27 | (m) | $1.12B | $213.77M | (m) | $708.86M | $299.10M | (m) |
| 2025-09-27 | (m) | $1.12B | $207.10M | (m) | $734.48M | $302.55M | (m) |
| 2025-06-28 | (m) | $1.08B | $182.82M | (m) | $767.57M | $279.55M | (m) |
| 2025-03-29 | (m) | $1.05B | $229.36M | (m) | $756.63M | $290.16M | (m) |
| 2024-12-28 | (m) | $994.10M | $194.61M | (m) | $720.91M | $278.54M | (m) |
| 2024-09-28 | (m) | $1.01B | $210.17M | (m) | $754.21M | $336.20M | (m) |
| 2024-06-29 | (m) | $947.52M | $179.21M | (m) | $762.22M | $349.11M | (m) |
| 2024-03-30 | (m) | $954.81M | $327.04M | (m) | $786.98M | $361.28M | (m) |
| 2023-12-30 | (m) | $1.06B | $276.77M | (m) | $780.38M | $380.26M | (m) |
| 2023-09-30 | (m) | $993.82M | $157.17M | (m) | $799.31M | $292.97M | (m) |
| 2023-07-01 | (m) | $1.01B | $200.44M | (m) | $800.65M | $285.28M | (m) |
| 2023-04-01 | (m) | $981.39M | $201.59M | (m) | $788.31M | $262.58M | (m) |
| 2022-12-31 | (m) | $1.09B | $233.91M | (m) | $752.39M | $255.81M | (m) |
| 2022-09-24 | (m) | $1.01B | $193.70M | (m) | $770.78M | $261.52M | (m) |
| 2022-06-25 | (m) | $1.05B | $200.32M | (m) | $747.61M | $256.76M | (m) |
| 2022-03-26 | (m) | $993.84M | $241.87M | (m) | $697.84M | $221.18M | (m) |
| 2021-12-25 | (m) | $1.03B | $241.21M | (m) | $642.88M | $199.15M | (m) |
| 2021-09-25 | (m) | $983.75M | $212.54M | (m) | $660.45M | $181.69M | (m) |
| 2021-06-26 | (m) | $929.61M | $222.97M | (m) | $644.03M | $194.34M | (m) |
| 2021-03-27 | (m) | $803.38M | $465.41M | (m) | $610.57M | $193.58M | (m) |
| 2020-12-26 | (m) | $839.75M | $228.42M | (m) | $617.74M | $185.69M | (m) |
| 2020-09-26 | (m) | $787.01M | $242.88M | (m) | $572.06M | $181.37M | (m) |
| 2020-06-27 | (m) | $727.94M | $402.02M | (m) | $532.53M | $168.37M | (m) |
| 2020-03-28 | (m) | $690.90M | $372.43M | (m) | $542.39M | $162.94M | (m) |
| 2019-12-28 | (m) | $710.18M | $238.01M | (m) | $514.03M | $160.66M | (m) |
| 2019-09-28 | (m) | $681.65M | $164.76M | (m) | $524.07M | $155.53M | (m) |
| 2019-06-29 | (m) | $635.60M | $200.59M | (m) | $545.15M | $134.93M | (m) |
| 2019-03-30 | (m) | $529.76M | $126.32M | (m) | $495.50M | $129.76M | (m) |
| 2018-12-29 | (m) | $558.22M | $195.44M | (m) | $472.25M | $127.89M | (m) |
| 2018-09-29 | (m) | $539.60M | $138.87M | (m) | $487.34M | $125.50M | (m) |
| 2018-06-30 | (m) | $518.14M | $192.30M | (m) | $478.74M | $124.13M | (m) |
| 2018-03-31 | (m) | $407.10M | $187.77M | (m) | $440.11M | $119.05M | (m) |
| 2017-12-30 | (m) | $463.50M | $163.79M | (m) | $430.02M | $114.96M | (m) |
| 2017-09-30 | (m) | $415.75M | $123.62M | (m) | $422.33M | $107.37M | (m) |
| 2017-07-01 | (m) | $424.07M | $116.47M | (m) | $398.55M | $104.69M | (m) |
| 2017-04-01 | (m) | $383.37M | $131.52M | (m) | $383.75M | $98.48M | (m) |
| 2016-12-31 | (m) | $429.59M | $117.63M | (m) | $364.05M | $95.83M | (m) |
| 2016-09-24 | (m) | $412.05M | $105.72M | (m) | $359.73M | $99.37M | (m) |
| 2016-06-25 | (m) | $413.39M | $154.59M | (m) | $345.54M | $98.12M | (m) |
| 2016-03-26 | (m) | $309.99M | $157.38M | (m) | $287.18M | $97.10M | (m) |
| 2015-12-26 | (m) | $311.76M | $117.95M | (m) | $270.07M | $93.73M | (m) |
| 2015-09-26 | (m) | $314.10M | $74.03M | (m) | $288.84M | $98.10M | (m) |
| 2015-06-27 | (m) | $276.53M | $150.81M | (m) | $277.40M | $90.04M | (m) |
| 2015-03-28 | (m) | $270.49M | $151.92M | (m) | $265.43M | $86.06M | (m) |
| 2014-12-27 | (m) | $296.17M | $160.02M | (m) | $257.99M | $89.04M | (m) |
| 2014-09-27 | (m) | $283.08M | $130.75M | (m) | $275.02M | $92.69M | (m) |
| 2014-06-28 | $403.37M | $271.65M | $117.01M | $11.86M | $274.50M | $92.62M | 1.48× |
| 2014-03-29 | $421.29M | $239.32M | $169.85M | $11.45M | $240.00M | $91.67M | 1.76× |
| 2013-12-28 | (m) | $247.03M | $155.93M | (m) | $220.63M | $89.40M | (m) |
| 2013-09-28 | $365.81M | $235.17M | $130.45M | $11.08M | $224.27M | $87.15M | 1.56× |
| 2013-06-29 | $344.48M | $225.85M | $113.52M | $6.93M | $224.03M | $88.41M | 1.53× |
| 2013-03-30 | $320.81M | $330.81M | $100.42M | $6.85M | $213.54M | $84.96M | 0.97× |
| 2012-12-29 | $319.47M | $342.25M | $109.69M | $6.78M | $203.00M | $88.47M | 0.93× |
| 2012-09-29 | $305.20M | $325.24M | $83.22M | $6.35M | $215.62M | $93.72M | 0.94× |
| 2012-06-30 | $290.75M | $328.13M | $76.08M | $6.62M | $208.05M | $92.28M | 0.89× |
| 2012-03-31 | $273.06M | $223.84M | $61.03M | $6.14M | $205.89M | $89.35M | 1.22× |
| 2011-12-31 | $259.07M | $216.80M | $68.91M | $5.36M | $184.81M | $92.97M | 1.20× |
| 2011-09-24 | $289.79M | $223.84M | $81.22M | $6.19M | $202.38M | $94.39M | 1.29× |
| 2011-06-25 | $370.03M | $277.10M | $145.83M | $11.78M | $212.42M | $100.53M | 1.34× |
| 2011-03-26 | (m) | $307.81M | $158.75M | (m) | $215.30M | $97.59M | (m) |
| 2010-12-25 | (m) | $259.78M | $179.16M | (m) | $192.97M | $100.30M | (m) |
| 2010-09-25 | (m) | $237.38M | $137.43M | (m) | $216.74M | $100.76M | (m) |
| 2010-06-26 | (m) | $246.06M | $219.08M | (m) | $218.69M | $96.57M | (m) |
| 2010-03-27 | (m) | (m) | $222.20M | (m) | (m) | (m) | (m) |
| 2009-12-26 | (m) | $249.77M | $182.57M | (m) | $196.95M | $102.72M | (m) |
| 2009-09-26 | (m) | (m) | $192.20M | (m) | (m) | (m) | (m) |
| 2009-06-27 | (m) | (m) | $154.81M | (m) | (m) | (m) | (m) |
| 2008-12-27 | (m) | (m) | $243.59M | (m) | (m) | (m) | (m) |
| 2007-12-29 | (m) | (m) | $225.45M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |